Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria
Main Article Content
Keywords
autoimmunity, chronic spontaneous urticarial, chronic urticarial, immunoglobulin E, omalizumab, urticaria control test
Abstract
Background: Omalizumab is a preferred treatment in antihistamine-refractory chronic spontaneous urticaria (CSU) patients. However, factors that may impact treatment response remain to be explored.
Objective: This study aimed to examine the factors affecting treatment response in CSU patients receiving omalizumab.
Methods: This was a retrospective study that included 123 patients who received omalizumab treatment for CSU between January 2015 and April 2024. After administering omalizumab, we evaluated therapeutic efficacy with the urticaria control test (UCT). According to UCT, patients were classified as complete responders, partial responders, and nonresponders.
Results: The median age of the patients was 42 (31–50) years, and there were 77 (62.9%) female patients. Sixty-four (52%) patients exhibited complete response, and 43 (35%) patients exhibited partial response to omalizumab treatment, whereas 16 (13%) patients were nonresponders. Autoimmune disease (AID) was present in 31 (25.2%) patients. The most common AID was thyroid autoimmunity, seen in 24 (77.4%) patients. AID was significantly higher in omalizumab treatment nonresponders than in partial and complete responders. The presence of an autoimmune thyroid disease was an independent risk factor for failure to respond to omalizumab treatment. Baseline IgE levels were significantly higher in omalizumab treatment responders with a complete response compared to those with a partial response and nonresponders.
Conclusion: Response to omalizumab treatment was influenced by the presence of an AID and baseline serum total IgE level. A concurrent autoimmune thyroid disease was found to be an independent risk factor affecting failed treatment response. Factors that can predict response to omalizumab treatment can help guide patients to more effective treatment.
References
2 Maurer M, Zuberbier T, Metz M. The classification, pathogenesis, diagnostic workup, and management of urticaria: An Update. Handb. Exp. Pharmacol. 2022;268:117–33. 10.1007/164_2021_506
3 He L, Yi W, Huang X, Long H, Lu Q. Chronic urticaria: Advances in understanding of the disease and clinical management. Clin. Rev. Allergy Immunol. 2021;61(3):424–48. 10.1007/s12016-021-08886-x
4 Larenas-Linnemann D. Biomarkers of autoimmune chronic spontaneous urticaria. Curr. Allergy Asthma Rep. 2023;23(12):655–64. 10.1007/s11882-023-01117-7
5 Kolkhir P, Muñoz M, Asero R, Ferrer M, Kocatürk E, Metz M, et al. Autoimmune chronic spontaneous urticaria. JACI. 2022;149(6):1819–31. 10.1016/j.jaci.2022.04.010
6 Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–66. 10.1111/all.15090
7 Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76(10):2965–81. 10.1111/all.14757
8 Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: A study of 470 patients. JEADV. 2019;33(5):918–24. 10.1111/jdv.15350
9 Bérard F, Ferrier Le Bouedec MC, Bouillet L, Reguiai Z, Barbaud A, Cambazard F, et al. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: Results of the phase IV open-label SUNRISE study. BJD. 2019;180(1):56–66. 10.1111/bjd.16904
10 Straesser MD, Oliver E, Palacios T, Kyin T, Patrie J, Borish L, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1386–8.e1. 10.1016/j.jaip.2017.10.030
11 Salameh P, Gutsche A, Aulenbacher F, Buttgereit T, Weller K, Siebenhaar F, et al. Urticaria control test real-world performance: A post-hoc analysis. Allergy. 2024;79(1):229–32. 10.1111/all.15813
12 Yu R, Qian W, Zheng Q, Xiong J, Chen S, Chen A, et al. Analysis of the efficacy and recurrence of omalizumab use in the treatment of chronic spontaneous urticaria and chronic inducible urticaria. Int. Arch. Allergy Immunol. 2023;184(7):643–55. 10.1159/000529250
13 Ghazanfar MN, Holm JG, Thomsen SF. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: A prospective study. JEADV. 2018;32(10):1761–7. 10.1111/jdv.15045
14 Ferrer M, Boccon-Gibod I, Gonçalo M, İnalöz HS, Knulst A, Lapeere H, et al. Expert opinion: Defining response to omalizumab in patients with chronic spontaneous urticaria. EJD. 2017;27(5):455–63. 10.1684/ejd.2017.3085
15 Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat. Rev. Dis. Primers. 2022;8(1):61. 10.1038/s41572-022-00389-z
16 Foti C, Romita P, Ambrogio F, Fanelli M, Panebianco R, Vena GA, et al. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria. Dermatol. Ther. 2022;35(2):e15248. 10.1111/dth.15248
17 Chen Q, Yang X, Ni B, Song Z. Atopy in chronic urticaria: An important yet overlooked issue. Fron. Immunol. 2024;15:1279976. 10.3389/fimmu.2024.1279976
18 Asero R. Omalizumab in severe chronic urticaria: Are slow and non-responders different? Eur. Ann. Allergy Clin. Immunol. 2021;53(6):263–6. 10.23822/EurAnnACI.1764-1489.167
19 Deza G, Bertolín-Colilla M, Pujol RM, Curto-Barredo L, Soto D, García M, et al. Basophil FcεRI expression in chronic spontaneous urticaria: A potential immunological predictor of response to omalizumab therapy. ActaDV. 2017;97(6):698–704. 10.2340/00015555-2654
20 Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review. Autoimmun. Rev. 2017;16(12):1196–208. 10.1016/j.autrev.2017.10.003
21 Bernstein JA, Kavati A, Tharp MD, Ortiz B, MacDonald K, Denhaerynck K, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: A systematic review of ‘real-world’ evidence. Expert Opin. Biol. Ther. 2018;18(4):425–48. 10.1080/14712598.2018.1438406
22 Weller K, Ohanyan T, Hawro T, Ellrich A, Sussman G, Koplowitz J, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy. 2018;73(12):2406–8. 10.1111/all.13586
23 Kolkhir P, Altrichter S, Asero R, Daschner A, Ferrer M, Giménez-Arnau A, et al. Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria. AAIR. 2021;13(4):545–59. 10.4168/aair.2021.13.4.545
24 Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy. 2017;72(10):1440–60. 10.1111/all.13182
